default author photo

Courtney Dinardo

University of Texas at Houston - Department of Leukemia

Houston, TX

United States

SCHOLARLY PAPERS

2

DOWNLOADS

146

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

IDH1 Mutation Enhances Catabolic Flexibility and Mitochondrial Dependencies to Favor Drug Resistance in Acute Myeloid Leukemia

Number of pages: 69 Posted: 18 Jan 2019
University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 1 - Laboratory of Engineering of Biological Systems and Processes (LISBP), University of Toulouse 1 - Laboratory of Engineering of Biological Systems and Processes (LISBP), National Infrastructure of Metabolomics and Fluxomics - MetaToul-MetaboHUB, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 1 - Laboratory of Engineering of Biological Systems and Processes (LISBP), Aix-Marseille University - Institut Paoli-Calmettes, MetaboHUB-Paris - Laboratoire d’Etude du Métabolisme des Médicaments, Proteome and Genome Reserch Unit, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Montpellier - Institute for Cancer Research in Montpellier, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Bordeaux - Fruit Biology and Pathology, University of Toulouse 1 - Toxalim INRA laboratory, University of Montpellier - Institute for Cancer Research in Montpellier, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Montpellier - Institute for Cancer Research in Montpellier, University of Texas at Houston - Department of Genomic Medicine, Louisiana State University, Baton Rouge - School of Medicine, University of Toulouse 1 - Laboratory of Engineering of Biological Systems and Processes (LISBP), University of Toulouse 1 - Laboratory of Engineering of Biological Systems and Processes (LISBP), MetaboHUB-Paris - Laboratoire d’Etude du Métabolisme des Médicaments, University of Montpellier - Institute for Cancer Research in Montpellier, University of Pennsylvania - Division of Hematology/Oncology, University of Pennsylvania - Division of Hematology/Oncology, Aix-Marseille University, Centre Hospitalier Universitaire (CHU) de Bordeaux - Clinical Hematology Service, Centre Hospitalier Universitaire (CHU) de Bordeaux - Clinical Hematology Service, Centre Hospitalier Universitaire (CHU) de Bordeaux - Biological Hematology Service, Aix-Marseille University - Institut Paoli-Calmettes, MetaboHUB-Paris - Laboratoire d’Etude du Métabolisme des Médicaments, University of Montpellier - Institute for Cancer Research in Montpellier, University of Montpellier - Laboratory of Physical Measurements, National Infrastructure of Metabolomics and Fluxomics - MetaToul-MetaboHUB, Onco-Occitanie Regional Oncology Network, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - MD Anderson Cancer Center, University of Montpellier - Institute for Cancer Research in Montpellier, University of Bordeaux - Fruit Biology and Pathology, Aix-Marseille University - Institut Paoli-Calmettes, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 1 - Laboratory of Engineering of Biological Systems and Processes (LISBP), National Infrastructure of Metabolomics and Fluxomics - MetaToul-MetaboHUB, University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center, University of Toulouse 1 - Laboratory of Engineering of Biological Systems and Processes (LISBP) and University of Toulouse 3, Paul Sabatier University - Toulouse Cancer Research Center
Downloads 101 (684,672)

Abstract:

Loading...

2.

A Phase II Study of Omacetaxine Mepesuccinate for Patients with Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia after Failure of Hypomethylating Agents

Number of pages: 56 Posted: 19 Jul 2018
University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Leukemia and University of Texas at Houston - Department of Leukemia
Downloads 45 (1,133,231)

Abstract:

Loading...

Myelodysplastic syndromes, chronic myelomonocytic leukemia, hypomethylating agents, omacetaxine mepesuccinate, homoharringtonine